Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

NCT00994318 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

626

Enrollment

INDUSTRY

Sponsor class

Conditions

Iron Deficiency Anaemia
Chronic Kidney Disease

Interventions

DRUG: FCM (Ferric carboxymaltose) high ferritin target
DRUG: FCM (Ferric carboxymaltose) low ferritin target
DRUG: Oral Iron (Ferrous sulphate)

Sponsor

Vifor Pharma

Collaborators

[object Object]
[object Object]